Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's Disease

Inclusion Criteria: 1. ethnic origin: Caucasian 2. age: 18 years or older 3. diagnosis of idiopathic Parkinson's disease 4. administration of a stable dose of at least 8 mg/24 h rotigotine including use of an 8 mg/24 h patch for at least 2 weeks prior to enrolment 5. agreement to refrain from swimming, bathing or using a sauna on the assessment days 6. written informed consent obtained, after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the patients participating in the clinical trial Exclusion Criteria: Safety concerns 1. existing and/or history of significant skin hypersensitivity to adhesives or other transdermal products 2. existing and/or history of dermatitis (eczema; excluding seborrheic skin by Parkinson's disease) 3. existing and/or history of psoriasis 4. existing and/or history of an active skin disease which interferes with the rotigotine patch application according to the investigator's assessment 5. history of or current drug or alcohol dependence 6. existing medical condition or psychiatric condition which, in the opinion of the investigator, could jeopardize or compromise the patient's well-being or ability to participate in this study 7. lifetime history of suicide attempt 8. suicidal ideation in the past 6 months 9. administration of any investigational medicinal product during the last 2 months prior to individual enrolment of the patient 10. diagnosis of COVID-19 within the last 14 days prior to individual enrolment of the patient 11. contact to persons in foreign risk regions as defined by the Robert Koch Institute within the last 14 days prior to individual enrolment of the patient 12. known direct contact with insufficient protection to persons with diagnosis of COVID-19 within the last 14 days prior to individual enrolment upon reporting of the patient For female patients with childbearing potential only: 13. positive pregnancy test at screening examination 14. pregnant or lactating women 15. female patients who do not agree to apply highly effective contraceptive methods Administrative reasons 16. patients suspected or known not to follow instructions 17. patients who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the clinical trial